2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Event Publication Document American Society for Hematology 1.4 MB MP0533: A CD3 Engager DARPin Targeting CD33, CD123 & CD70 for the Treatment of AML and MDS Society for the Immunotherapy of Cancer’s Annual meeting 1.8 MB SITC 2022: Interim analysis of a phase 1 study with MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors Nature Biotechnology 4.9 MB The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants European Hematology Association - EHA2022 Congress 721.1 KB MP0533, A New Multispecific DARPin CD3 Engager Targeting Three Tumor Associated Antigens Induces Specific T-cell Activation And AML Tumor Killing In Vivo Antibody Engineering & Therapeutics EUROPE 4.6 MB Ensovibep, a SARS-CoV-2 Multi-Variant Neutralizing DARPin Therapeutic American Society for Microbiology: ASM MICROBE 1.3 MB SARS-CoV-2 Omicron And Multi-variant Neutralization Activity Of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid-19 (a Novartis poster presentation) GRC: Dissecting Evolution and Heterogeneity of Single Cancer Cells 2.5 MB Characterization of Tumor Infiltrating Dendritic Cells at the Single Cell Level ISAR-ICAR2022: 35TH International Conference on Antiviral Research 657.3 KB SARS-CoV-2 Omicron and Pan-Variant Neutralization Activity of Ensovibep: a DARPin Therapeutic Candidate for Treatment of Covid-19